18th Dec 2015 16:20
TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES | ||||
1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached: | Alliance Pharma Plc | |||
2 Reason for the notification (please tick the appropriate box or boxes): | ||||
An acquisition or disposal of voting rights | ü | |||
An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached | ||||
An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments | ||||
An event changing the breakdown of voting rights | ||||
Other (please specify): | ||||
3. Full name of person(s) subject to thenotification obligation: | FMR LLC | |||
4. Full name of shareholder(s) (if different from 3.): | See Section 9 | |||
5. Date of the transaction and date onwhich the threshold is crossed orreached: | 17th December 2015 | |||
6. Date on which issuer notified: | 18th December 2015 | |||
7. Threshold(s) that is/are crossed orreached: | 5% | |||
8. Notified details: | ||||||||||||||||
A: Voting rights attached to shares | ||||||||||||||||
Class/type ofshares if possible usingthe ISIN CODE | Situation previousto the triggeringtransaction | Resulting situation after the triggering transaction | ||||||||||||||
NumberofShares | NumberofVotingRights | Numberof shares | Number of votingrights | % of voting rights | ||||||||||||
Indirect | Direct | Indirect | Direct | Indirect | ||||||||||||
GB0031030819 | 11,036,203 | 11,036,203 | 26,036,203 | 26,036,203 | 5.56% | |||||||||||
B: Qualifying Financial Instruments | ||||||||||||||||
Resulting situation after the triggering transaction | ||||||||||||||||
Type of financialinstrument | Expirationdate | Exercise/Conversion Period | Number of votingrights that may beacquired if theinstrument isexercised/ converted. | % of votingrights | ||||||||||||
C: Financial Instruments with similar economic effect to Qualifying Financial Instruments | ||||||||||||||||
Resulting situation after the triggering transaction | ||||||||||||||||
Type of financialinstrument | Exercise price | Expiration date | Exercise/Conversion period | Number of voting rights instrument refers to
| % of voting rights
| |||||||||||
| Nominal | Delta | ||||||||||||||
Total (A+B+C) | ||||||||||||||||
Number of voting rights | Percentage of voting rights | |||||||||||||||
26,036,203 | 5.56 | |||||||||||||||
9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: | ||||||||||||||
| ||||||||||||||
Proxy Voting: | ||||||||||||||
10. Name of the proxy holder: | ||||||||||||||
11. Number of voting rights proxy holder will acquire: | ||||||||||||||
12. Date on which proxy holder will acquire voting rights: | ||||||||||||||
13. Additional information: | None | |||||||||||||
14. Contact name: | Sally- Ann Hatton | |||||||||||||
15. Contact telephone number: |
[email protected], 01737 837148
| |||||||||||||
Related Shares:
Alliance Pharma